Prognostic Value of Bcl-2 and Bax Tumor Cell Expression in Patients with Non Muscle-Invasive Bladder Cancer Receiving Bacillus Calmette-Guerin Immunotherapy

REFERENCES

• Herr HW, Wartinger DD, Fair WR, Oettgen HF. Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year follow-up. J Urol. 1992;147:1020–1024.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168:1964–1970.
   PubMed Web of Science ®Google Scholar
• Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol. 2003;169:96–100.
   PubMed Web of Science ®Google Scholar
• Lebret T, Bohin D, Kassardjian Z, et al. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. J Urol. 2000;163:63–67.
   PubMed Web of Science ®Google Scholar
• Becich MJ, Carroll S, Ratliff TL. Internalization of bacilli Calmette-Guérin by bladder tumor cells. J Urol. 1991;145: 1316–1324,.
   PubMedGoogle Scholar
• Ikeda N, Toida I, Iwasaki A, Kawai K, Akaza H. Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Guerin (BCG): a role of BCG internalization into tumor cells. Int J Urol. 2002;9: 29–35.
   PubMedGoogle Scholar
• Alvarez V, Lodillinsky C, Umerez S, Sandes E, Eiján AM. Inhibition of bacillus Calmette-Guerin induced nitric oxide in bladder tumor cells may improve BCG treatment. Int J Mol Med. 2005;16: 565–571.
   PubMedGoogle Scholar
• Papageorgiou A, Lashinger L, Millikan R, et al. Role of tumor necrosis factor-related apoptosis-inducing ligand in interferoninduced apoptosis in human bladder cancer cells. Cancer Res. 2004;64: 8973–8979.
   PubMedGoogle Scholar
• Sandes E, Lodillinsky C, Cwirenbaum, R, Arguelles, C, Casabe, A, Eijan, AM. Cathepsin B is involved in the apoptosis intrinsic pathway induced by Bacillus Calmette-Guérin in transitional cancer cell lines. (2007); 20(6);823–828.
   Google Scholar
• Chen F, Zhang G, Iwamoto Y, et al. BCG directly induces cell cycle arrest in human transitional carcinoma cell lines as a consequence of integrin cross-linking. BMC Urol. 2005;5:8.
   PubMedGoogle Scholar
• Chen F, Zhang G, Cao Y, et al. Bacillus Calmette-Guerin inhibits apoptosis in human urothelial carcinoma cell lines in response to cytotoxic injury. J Urol. 2007;178:2166–2170.
   PubMedGoogle Scholar
• See WA, Zhang G, Chen F, et al. BCG induces necrotic cell death in urothelial carcinoma cells associated with the release of the chemokine HMGB1. J Urol. 2007;179(Suppl 4):370.
   Google Scholar
• Arends MJ, Wyllie AH. Apoptosis: mechanisms and roles in pathology. Int Rev Exp Pathol. 1991; 32: 223–254.
   PubMedGoogle Scholar
• Vaux DL. Toward an understanding of the molecular mechanisms of physiological cell death. Proc Natl Acad Sci USA. 1993; 90: 786–789.
   PubMed Web of Science ®Google Scholar
• Goldszmid RS, Idoyaga J, Bravo AI, Steinman R, Mordoh J, Wainstok R. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanome. J Immunol. 2003;171: 5940–5947.
   PubMed Web of Science ®Google Scholar
• Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998;392: 86–89.
   PubMed Web of Science ®Google Scholar
• King ED, Matteson J, Jacobs SC, Kyprianou N. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J Urol. 1996; 155:316.
   PubMed Web of Science ®Google Scholar
• Lipponen PK, Aaltomaa S Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol. 1994;173:333.
   PubMed Web of Science ®Google Scholar
• Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74: 609–619.
   PubMed Web of Science ®Google Scholar
• McDonnel TJ, Troncoso P, Brisbay SM, et al. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgene-independent prostate cancer. Cancer Res.1992; 52: 6940–6944.
   PubMedGoogle Scholar
• Gazzaniga P, Gradilone A, Vercillo R, et al. Bcl-2/Bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer. Int J Cancer. 1996; 69: 100–104.
   PubMed Web of Science ®Google Scholar
• Krajewska M, Fenoglio Preiser CM, Krajewski S, et al. Immunohistochemical analysis of Bcl-2 family proteins in adenocarciomas of the stomach. Am J Pathol. 1996a;149:1449–1457.
   PubMed Web of Science ®Google Scholar
• Xie X, Clausen OPF, De Angelis P, Boysen M. Bax expression has prognostic significance that is enhanced when combined with Ag NOR counts in glottic carcinomas. Br J Cancer. 1998; 78: 100–105.
   PubMedGoogle Scholar
• Gonzalez-Campora R, Davalos-Casanova G, Beato-Moreno A, et al. Apoptotic and proliferation indexes in primary superficial bladder tumors. Cancer Lett. 2006; 242: 266–272.
   PubMedGoogle Scholar
• Glick SH, Howell LP, White RW, Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder J Urol. 1996;155: 1754–1757.
   PubMed Web of Science ®Google Scholar
• Maluf FC, Cordon-Cardo C, Verbel DA et al. Assessing interactions between mdm2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by loco-regional surgical treatment. Ann Oncol. 2006;19: 1–10.
   Google Scholar
• Ioakim-Liossi A, Pantazopoulos D, Karakitsos P et al. P53 protein expression and proliferative activity in imprints of superficial transitional cell carcinoma of the bladder. Anal Quant Cytol Histol. 2000;22: 223–228.
   PubMedGoogle Scholar
• Amirghofran Z, Monabati A, Khezri A, Malek-Hosseini Z. Apoptosis in transitional cell carcinoma of bladder and its relation to proliferation and expression of p53 and bcl-2. Pathol Oncol Res. 2004;10: 154–158.
   PubMedGoogle Scholar
• Atug F, Turkeri L, Ozyurek M, Akdas A. Bcl-2 and p53 overexpression as associated risk factors in transitional cell carcinoma of the bladder. Int Urol Nephrol. 1998;30: 455–461.
   PubMedGoogle Scholar
• Korkolopoulou P, Lazaris AC, Konstantinidou AE, et al. Differential expression of bcl-2 family proteins in bladder carcinomas: relationship with apoptotic rate and survival,. Eur Urol. 2002; 41: 274–283.
   PubMedGoogle Scholar
• Matsumoto H, Wada T, Fukunaga K, Yoshihiro S, Matsuyama H, Naito K. Bax to Bcl-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer. Jpn J Clin Oncol. 2004; 34:124–130.
   PubMed Web of Science ®Google Scholar
• Nakopoulou L, Vourlakou C, Zervas A, Tzonou A, Gakiopoulou H, Dimopoulos MA. Gakiopoulou, M.A. Dimopoulos. The prevalence of bcl- 2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol. 1998;29:146–154.
   PubMed Web of Science ®Google Scholar
• Shiina H, Igawa M, Urakami S, Honda S, Shirakawa H, Inhibe T. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder. J Clin Pathol. 1996; 49: 395–399.
   PubMedGoogle Scholar
• Okamura T, Akita H, Hawai N, Tozada K, Yamada Y, Kohri K. Immunohistochemical evaluation of p53, proliferating cell nuclear antigen (PCNA) and bcl-2 expression during Bacillus Calmette–Guerin (BCG) intravesical instillation therapy for superficial bladder cancers. Urol Res. 1998;26: 161–164.
   PubMedGoogle Scholar
• Daas M, del Rosario AD, Bui HX, Sing JK, Ross JS. Bcl-2 protein expression is related to cellular differentiation in urinary bladder transitional cell carcinoma (UB-TCC). United States and Canadian Academy of Pathology, Annual Meeting, Toronto. Abstract No 423, 1995;74A.
   Google Scholar
• Hussain SA, Ganesan R, Hiller L et al. Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder. Br J Cancer. 2003;88: 586–592.
   PubMed Web of Science ®Google Scholar
• Sauter G, Algaba F, Amin MB et al. Non invasive urothelial tumors. In: Elbe JN, Sauter G, Epstein JI, Sesterhenn IA, eds. Pathology and Genetics. Tumors of the Urinary System and Male Genital Organs. Lyon:IARC; 2004: 110–111.
   Google Scholar
• Brandau S, Bohle A. Bladder cancer: molecular and genetic basis of carcinogenesis. Eur Urol. 2001;39:491–497.
   PubMed Web of Science ®Google Scholar
• Martinez-Pineiro JA, Flores N, Isorna S, et al; for CUETO (Club Urologico Espanol de Tratamiento Oncologico). Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacilli Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int, 2002;89:671–680.
   PubMed Web of Science ®Google Scholar
• Akaza H, Hinotsu S, Aso Y, Kakizoe T, Koiso K. Bacillus Calmette-Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder: four-year results. The Bladder Cancer BCG Study Group. Cancer. 1995;75:552–559.
   PubMed Web of Science ®Google Scholar
• Davis JW, Sheth SI, Doviak MJ, Schellhammer PF. Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with 10-year minimum follow-up. J Urol. 2002;167:494–501.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Campora R, Davalos-Casanova G, Beato-Moreno A, et al. BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma. Cancer Lett. 2007;250:292–299.
   PubMedGoogle Scholar
• Chang HE, Jung KH, Kim DY, et al. Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma. Hum Pathol. 2005;36: 364– 371.
   PubMedGoogle Scholar
• LI-Yang Khor, Michelle D, Rille LI, et al. Bcl-2 and Bax expression and prostate cancer outcome in men treated with radiotherapy in radiation therapy oncology group protocol 86-10; Clin Invest. 2006;66: 1, 25–30.
   Google Scholar